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Abstract
Background: Obesity has been associated with increased mortality from hormone dependant cancers such as breast cancer which is the 
most prevalent cancer in women. The link between obesity and breast cancer can be attributed to excess estrogen produced through 
aromatization in adipose tissue. The role of steroid hormone receptors in breast cancer development is well studied but how obesity can 
affect the expression pattern of steroid hormones in patients with different grades of breast cancer was the aim of this study.
Methods: In this case-control study, 70 women with breast cancer participated with different grades of obesity (36 none obese, 
BMI , 25 kg/m2 and 34 obese, BMI $ 25 kg/m2). The mean age of participants was 44.53 ± 1.79 yr (21–70 yr). The serum level of 
estrogen, progesterone and androgen determined by ELISA. Following quantitative expression of steroid hormone receptors mRNA in 
tumor tissues evaluated by Real-time PCR. Patients with previous history of radiotherapy or chemotherapy were excluded. SPSS 16 was 
used for data analysis and P , 0.05 considered statistically significant.
Results: The difference in ERα, ERβ and PR mRNA level between normal and obese patients was significant (P , 0.001). In addition, 
the expression of AR mRNA was found to be higher than other steroid receptors. There was no significant relation between ERβ gene 
expression in two groups (P = 0.68). We observed a significant relationship between ERα and AR mRNA with tumor stage and tumor 
grade, respectively (P = 0.023, P = 0.015).
Conclusion: According to the obtained results, it is speculated that obesity could paly a significant role in estrogen receptors gene 
expression and also could affect progression and proliferation of breast cancer cells.
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Introduction
Obesity, which is the accumulation of excessive adi-
pose tissue, is closely associated with an increased 
risk of cardiovascular morbidities, including hyper-
tension,  atherosclerosis  and  other  vascular 
  complications.1 Obese subjects have not only increased 
risk of developing cancer, but their mortality is also 
increased with increasing BMI, especially when the 
BMI is .40 kg m2.2,3 Adiposity or abnormality of 
body fat distribution is considered to be one of the 
major risk factors for breast cancer in postmenopausal 
women.4 The adipose tissue of obese women secretes 
more biologically active estrogen to stimulate mam-
mary epithelial cell mitosis and to promote the devel-
opment of the tumor.5 While breast cancer imposes a 
significant healthcare burden on women worldwide so 
early detection is of paramount importance in reduc-
ing  mortality,  yet  the  diagnosis  of  breast  cancer  is 
hampered by the lack of an adequate detection   method.6 
In addition, better breast cancer prognostication may 
improve  selection  of  patients  eligible  for  adjuvant 
therapy.7  Hence,  new  markers  for  early  diagnosis, 
accurate prognosis and prediction of response to treat-
ment are warranted to improve breast cancer care. The 
importance of Estrogen Receptor (ER) status as an 
independent prognostic factor in breast cancer is well 
established8,9  and  using  immunohistochemical  tech-
niques, it is now routinely determined in breast cancer 
prognosis, that if positive, tumor will respond better to 
anti-estrogen  therapy.10,11  It  is  well  established  that 
estrogens mediate their effects through two receptors 
ERα and ERβ, with seemingly opposing effects in 
vitro, ie, ERα mediating proliferative and ERβ medi-
ating anti-proliferative effects.12 In contrast to numer-
ous studies that revealed undeniable impact of obesity 
on poor prognosis of disease in heavier   subjects, the 
possible effect of obesity on ERs gene expression is 
not elucidated yet. For now a handful of studies inves-
tigated  the  possible  impact  of  obesity  on  estrogen 
receptors gene expression and prognosis of diseases in 
patients. Interestingly, it seems that ER positive tumors 
are more likely to be associated with obesity than are 
ER negative tumors.13,14 Furthermore, obesity is asso-
ciated with poor prognosis in both pre and post meno-
pausal breast cancer.15,16 Since most breast cancers in 
obese patients are ER+/PR+ and these receptor posi-
tive cancers have a better   prognosis, breast cancers 
occurring in obese patients should be expected to be 
less aggressive. But this is not always the case, one 
possible explanation is that the increased estrogen lev-
els in obese patients may stimulate tumor growth and 
adversely affect the   prognosis.17 The hormonal envi-
ronment in obese women is consistent with the finding 
that obese women with breast cancer more frequently 
develop metastases and have a shorter survival time 
than non-obese breast cancer patients.18
The reasons why breast cancer in obese patients is 
more frequently ER+/PR+ is unknown. On the other 
more  of  these  ER-/PR-  tumors  express  androgen 
receptor at high levels. Obesity is reported to be asso-
ciated with an increased incidence of hormone recep-
tor  positive  tumors  in  some  studies  while  others 
suggest  an  increase  of  hormone  receptor  negative 
tumors.14 This discrepancy may be explained by dif-
ferences in laboratory techniques or criteria for hor-
mone responsiveness.19
Beside ER gene expression, the role of other sto-
ried hormones such as Progesterone and androgen 
receptors in breast cancer development are well stud-
ied but the possible role of obesity on expression of 
these steroid receptors is not clear. For now only a 
few studies investigated the correlation between obe-
sity and total ER at protein level. In this study we 
used Real Time PCR as a reliable and robust tech-
nique to evaluate the expression pattern of steroid 
hormone  receptors  gene  expression  in  normal  and 
obese  breast  cancer  patients  to  study  the  possible 
impact of obesity on steroid hormones gene expres-
sion, and to evaluates if these findings are in concor-
dance to the findings of protein based methods.
Materials and Methods
Patients and samples
This study was a descriptional cross sectional study. 
All  samples  were  obtained  from  70  women  who 
underwent biopsy or mastectomy surgical operation 
at Tabriz Emam Reza Hospital from July 2009 until 
May 2010. The whole project carried out in Tabriz 
Drug Applied  Research  Center. The  samples  were 
examined  histologically  for  the  presence  of  tumor 
cells by a pathologist. The patients met the following 
criteria: primary unilateral non metastatic breast car-
cinoma for which complete clinical, histological and 
biological data were available; and no radiotherapy or 
chemotherapy  before  surgery.  After  the  interview, 
during surgery tumor tissue samples were taken into Obesity and steroid receptors gene expression in breast cancer patients
Breast Cancer: Basic and Clinical Research 2011:5  229
liquid nitrogen in sterile tubes, then as soon as   possible 
aliquated  and  stored  at  -70  °C  until  subsequent 
  analysis. In order to reduce the influence of treatment 
on measurements, questionnaire data was obtained 
prior surgery.
Body mass index (BMi)
Accordingly WHO Rep 2000 (World Health Organi-
zation, 2000), BMI was calculated as kg/m2 using 
information from clinical notes at time of diagnosis. 
In the analyses, BMI was divided into two categories: 
BMI , 25 kg/m2 (non-obese) and BMI $ 25 kg/m2 
(obese).
Collection of questionnaire  
data- tumor tissues
After patients were approved to participate, written 
informed consent was obtained from all subjects. All 
participants  undertook  to  fill  in  questionnaire. 
It took information on social demographic character-
istics, age, age of menark, menstrual history, body 
mass index and menopause status. The study was 
blind and data collectors were unaware of the study 
  hypothesis. All participants were also measured for 
height and weight via standardized techniques. BMI, 
as an indicator of generalized obesity, was calculated 
as  weight  in  kilograms  divided  by  the  square  of 
height in meter.
Sample preparation
Immediately after the interview, a 10 ml blood sample 
was drawn into coded EDTA-treated tubes and centri-
fuged at 3000 rpm for 10 min at room temperature 
within 1 h of collection. Plasma, Buffy coat and red 
blood cells were separated and stored at -70 °C until 
subsequent analysis. To avoid the influence of treat-
ment on measurements, questionnaire data and blood 
specimens were obtained prior to initiation of defini-
tive breast cancer therapy including surgery and/or 
radio- or chemotherapy.
Steroid hormones level  
(plasma estrogen, androgen  
and progesterone levels)
Plasma concentrations of estrogen, androgen and pro-
gesterone were determined by the use of commer-
cially available quantitative sandwich enzyme-linked 
immunosorbant assay (ELISA) kits (DRG Estradiol 
ELISA,  EIA  2693,  DRG  Progesterone  ELISA, 
EIA1561  and  DRG  Androgen  ELISA,  EIA-1559 
  Germany).  The  sensitivity  of  this  assay  was 
9.714 pg/ml for estradiol, for both progesterone and 
androgen was 0.083 ng/ml. Masked split specimens 
included within each batch were used to calculate the 
coefficient  of  variation  (CV)  within  and  between 
batches: the intra- and inter-assay CVs of estaradiol, 
progesterone and androgen were below 6.81% and 
7.25%,  5.4%  and  9.96%  and  4.16%  and  9.94%, 
respectively. All matched blood samples were   handled 
identically and assayed in the same analytical run. 
The blood samples were labeled by number only and 
ordered randomly within each case–control pair.
Preparation of total RnA
Approximately 100 mg of tissue from each tumor was 
quick frozen in liquid nitrogen and pulverized manu-
ally with a hammer to a fine powder. The cells pow-
der were harvested and resuspended in 1 ml of RNX 
plus reagent in a clean RNase-free tube. After incuba-
tion for 5 minutes at room temperature the sample 
was done pipetteing and subsequently treated with 
adding 200 µl of chloroform and was taken at room 
temperature for 5 minutes after shaking rigorously for 
15 seconds. The mixture was centrifuged at 12,000 × g 
for 15 minutes and then the aqueous phase containing 
the RNA was transferred to a clean RNase-free tube. 
The total RNA was precipitated by adding 0.5 ml of 
isopropyl alcohol and incubated at room temperature 
for 15 minutes. The pellet including total RNA was 
washed  by  using  75%  ethanol  and  centrifuge  at 
7,500 × g for 8 minutes. After drying ethanol, the 
RNA pellet re-suspended in TE buffer. The concen-
tration  of  total  RNA  was  calculated  based  on 
OD260/280 ratio measurements as a means to address 
purity of RNA.
cDnA synthesis
RNA  was  converted  to  cDNA  after  treating  with 
DNase I. Reverse transcription of RNA was done in a 
final volume of 20 µl by using of cDNA first strand 
synthesis  kit  (Fermentase)  random  hexamere  and 
1 µg of total RNA. The samples were incubated at 
65 °C for 10 min and 42 °C for 60 min, and reverse 
transcriptase was inactivated by heating at 70 °C for 
5 min and cooling at 4 °C for 5 min.esfahlan et al
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Real-time RT- PCR
Principle: reactions are characterized by detection 
of cycling amplification of the PCR product, rather 
than the amount of PCR product accumulated after 
a fixed number of cycles. If the amount of the target 
molecule was larger, the earlier a significant increase 
in  fluorescence  is  observed.  The  parameter  Ct 
(threshold cycle) is defined as the cycle number at 
which the fluorescence generated by cleavage of the 
probe  passes  a  fixed  threshold  above  baseline. 
We  used  the  ∆∆CT  method  for  determination  of 
relative ERs gene expression. The Ct of each target 
gene compared to the Ct of it’s internal control (beta 
actin gene).
Final results, expressed as N-fold differences in 
tested  gene  (obese)  relative  to  control  gene  (none 
obese), termed “N fold changes,” were determined as 
follows:
N fold changes = 2(∆Ct Test - ∆Ct control)
where ∆Ct values of the sample and control are deter-
mined by subtracting the average Ct value of the tar-
get gene from the average Ct value of the beta actin 
gene.
qRT-PCR assay: generation  
of standards for target gene
To be sure of equal efficiency of PCR assay, serial 
dilutions of one sample that expressed target gene in 
high levels selected and standard curve for both ERs 
and control gene were prepared. PCR efficiency for 
both control and target gene was acceptable. More-
over, Melting curve analysis showed that there was 
only one segment (one pick) and this is an   indication 
for amplification of desired specific PCR product in 
our study.
After determination of RNA concentration based 
on  absorbance  and  cDNA  synthesis,  the  precise 
amount of cDNA was added to each reaction mix. 
  Quantitative detection of mRNA molecules was deter-
mined by quantitative real-time RT-PCR technique 
using the Syber Green-I (Fermentase Co. according 
to the instructions) by the Rotor-GeneTM 6000 system 
(Corbett Research, Australia) according to the manu-
facturer’s instructions. After cDNA synthesis, specific 
primers were used to amplify ERs and steroid hor-
mone receptors progesterone and androgen receptor. 
(Primer sequences shown in Table 1). Human beta 
actin mRNA was selected as the housekeeping gene 
(reference gene) and amplified by using the specific 
forward and reverse primers. The Beta-actin mRNA 
measured as an internal control (a mRNA that does 
not vary in abundance respective to cell type) was 
included in each analysis. Briefly, each sample was 
normalized to the number of cells harvested. The pro-
tocol for detection of RNA consisted started by dena-
tured at 95 °C for 10 minutes. This step was followed 
by 40 cycles of denaturing at 95 °C for 15 second; 
annealing at 60 °C for 30 seconds; extending at 72 °C 
for 30 seconds, which was then followed by melting 
curve  analysis  of  70  °C  to  95  °C  for  conformity 
assessment.
Statistical analysis
Differences between obese and non-obese groups in 
age at enrollment, age at menarche, age at menopause 
were  tested  using  the  chi-square  test.  In  addition, 
  Student’s t-test was used to evaluate differences in 
categorical breast cancer risk factors between obese 
Table 1. Primer sequences for RT-real Time PCR.
mRnA primer sequence product size Reference
eRα TgA TgA AAg gTg ggA TAC gA 
AAg gTT ggC AgC TCT CAT gT
125 bp Pfeiler et al34
eRβ gCT TAg Tgg AgC TCA gCC Tg 
AggATCATggCCTTgACACAgA
262 bp Pffafl et al35
PR gAACCAgATgTgATCTATgCAggA 
CgAAAACCTggCAATgATTTAgAC
122 bp Cremoux et al28
AR CCTggCTTCCgCAACTTACAC 
ggACTTgTgCATgCggTACTCA
168 bp Bieche et al27
Beta actin TCCCTggAgAAgAgCTACg 
gTAgTTTCgTggATgCCACA
134 bp genbank accession: 
nM_001101Obesity and steroid receptors gene expression in breast cancer patients
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Table 2. Characteristics of obese and non-obese breast cancer patient.
Baseline characteristics none obese (n = 36) 
Mean ± se
Obese (n = 34) 
Mean ± se
P value
Age at enrollment (yr) 43.82 ± 1.78 45.42 ± 2.27 0.45
BMi (kg/m2) 23.23 ± 0.23 29.80 ± 0.63 0.000
Family history of breast cancer  no. (%) no. (%)
  Yes 18 (54.5) 6 (22.2)
  no 15 (45.5) 21 (77.8) 0.01
Family history of obesity
  Yes 23 (69.7) 22 (81.5)
  no 10 (30.3) 5 (18.5) 0.22
Menopause status
  Premenopausal 21 (63.6) 12 (46.2)
  Postmenopausal 12 (36.4) 14 (53.8) 0.14
Age at first live birth (yr)  
  17. 
 
12 (37.5) 
 
12 (48.0)
  18–23 11 (34.4) 10 (40) 0.32
  24, 9 (28.1) 3 (12)
Age at menarche (yr)
  12. 10 (30.3) 6 (23.1)
  13 5 (15.2) 10 (38.5) 0.12
  14, 18 (54.5) 10 (38.5)
and non-obese. Pearson correlation coefficients were 
used to examine cross-sectional relationships between 
steroid receptors, gene expression and BMI among 
subjects. Chi-square test was performed to test the 
relation between steroid receptors mRNA level and 
clinicopathological parameters (For this purpose, all 
steroid  receptors  according  to  their  mRNA  con-
tent  divided  in  two  subgroups  as  low  and  high 
mRNA level). All statistical analysis was conducted 
using SPSS statistical software (version 16). P val-
ues below the conventional level of statistical signifi-
cance  (P  ,  0.05)  were  considered  statistically 
significant.
Results
In this case-control study, 70 women with breast can-
cer  participated  with  different  grades  of  obesity 
(36  none  obese,  BMI  ,  25  kg/m2  and  34  obese, 
BMI $ 25 kg/m2). The mean age of participants was 
44.53 ± 1.79 yr (range from 21–70 years old) and half 
of  them  were  under  44  years  old  at  the  time  of 
enrollment. Patients with previous history of radio-
therapy  or  chemotherapy  were  excluded  from  this 
study. Our results indicated that there is a significant 
relationship between family history of breast cancer 
and breast cancer risk in patients (P = 0.01). Base-
line characteristics are summarized in Table 2. About 
subtypes of breast cancer samples, 71% of tumors were 
DCIS and 28.3% were LCIS and CIS. Although we 
observed no significant relationship between obesity 
and none of clinicopathological parameters (P . 0.05) 
but more of low grade tumors observed in non-obese 
cases (63.6%), while more of high grade tumors pre-
sented in obese ones (58.5%) (see Table 3). Moreover 
in case of tumor size, while more small size tumors 
(,2 cm) observed in none obese cases (51.9%), more 
of the obese ones had a tumor diameter of $2 cm 
(52.8%) (Data not shown).
Serum level of estrogen, progesterone 
and androgen in blood samples
We analyzed serum level of estrogen, progesterone 
and  androgen  in  70  cases  with  breast  cancer. The 
mean-  ±  SE  serum  level  of  estrogen  was 
117.81 ± 17.81 in none obese (n = 33) 149.83 ± 54.75 
vs. in obese cases (n = 37), and mean ± SE progester-
one was 0.96 ± 0.26 vs. 1.60 ± 0.63 and also the serum 
level of Androgen was 1.56 ± 0.042 vs. 1.57 ± 0.02. 
The mean serum level of estrogen and progesterone 
was higher in obese cases (P = 0.07 and P = 0.03 
respectively) (see Table 4).
As  a  result,  there  was  a  significant  correlation 
between serum level of estrogen and progesterone 
with  ERα  mRNA  (Spearman  2  tailed  correlation esfahlan et al
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r = 0.409, P = 0.00, n = 66 and r = 0.85, P = 0.00 and 
n  =  70  respectively)  but  no  significant  correlation 
observed between ERβ and serum level of steroid 
hormones (P . 0.05).
Determination of progesterone,  
androgen and estrogen receptors  
(eRα and eRβ) gene expression  
in breast cancer tissues
Results  of  comparison  of  steroid  hormones  mRNA 
level between obese and non-obese cases according to 
∆C values are summarized in Table 5. It is obvious that 
as the ∆C value is high, so the expression of target gene 
will  be  less. According  to  this  table, obese subjects 
expressed a higher level of ERα and also progesterone 
receptors in comparison to non-obese subjects and the 
difference in ERα and PR mRNA level between these 
two groups of patients was significant (both P , 0.001). 
In case of ERβ, the expression of ERβ was lower in 
obese  ones  and  the  difference  in  ERβ  mRNA  level 
between  two  groups  was  statistically  significant 
(P , 0.001). There was no difference in AR mRNA 
between obese and none obese cases (P = 0.40). Through 
these steroid receptors, the ERβ mRNA show the low-
est and AR mRNA show the highest expression in stud-
ied samples. 2∆∆Ct values of ERα, ERβ, PR and AR 
were 1–35, 1–11, 1–5 and 1–2.4 respectively.   Standard 
curve and amplification of one of the steroid hormone 
receptors is (ERβ) represented in Figures 1 and 2.
Moreover,  a  two  tailed  Pearson  coefficient  test 
shows that there was a significant correlation between 
ERα, ERβ and PR mRNA level and BMI in samples 
(rs = 0.56, n = 70 and P = 0.00, rs = -0.56, n = 70 and 
P = 0.00 and rs = 0.49, n = 70 and P = 0.00). There was 
no  correlation  between  AR  and  BMI  in  subjects 
(rs = -0.09, n = 70, P = 0.45). Moreover we observed 
a positive correlation between ERα and PR in samples 
(rs = 0.89, n = 70 and P = 0.00). Two tailed Pearson 
coefficient test shows that there was a positive correla-
tion between AR mRNA and ERα and PR mRNA 
(rs = 0.23, n = 69, P = 0.04 and rs = 0.34, n = 69, 
P = 0.004 respectively) but no correlation observed 
between AR and ERβ mRNA level (P . 0.05).
Relation between steroid hormone 
receptors gene expression with 
clinicopatological parameters
According to the Bloom Richardson classification for 
classifying the tumors, the tumors were classified into 
6 stages and 3 grades.20–22 To evaluate the possible 
relationships  between  steroid  hormone  receptors 
mRNA level and clinical characteristics of the tumor; 
ie,  clinical  staging  and  histopathological  grading, 
analysis  was  performed  using  chi  square  test 
(Tables 6 and 7). For this purpose, all steroid recep-
tors according to their mRNA content were divided in 
two  subgroups  as  low  and  high  mRNA  level.  We 
found  a  significant  relationship  between  ERα  and 
tumor stage and also a significant relation between 
AR gene expression and tumor grade in breast cancer 
tumors (P = 0.045 and P = 0.046 respectively) but 
there was no significant relation between ERβ and PR 
with clinocopathological parameters.
conclusion
Many studies have evaluated the possible role of 
obesity  on  some  steroid  hormones  via  protein 
Table 4. Mean ± Se serum level of steroid hormones.
Mean ± se 
sterid hormone
none obese 
(BMI , 25 kg/m2) 
(n = 36)
Obese cases 
(BMI $ 25 kg/m2) 
(n = 36)
P
estrogen (pg/ml) 117.81 ± 17.81 149.83 ± 54.75 0.07
Progesterone (ng/ml)     0.96 ± 0.26      1.60 ± 0.63 0.03
Androgen (ng/ml)     1.56 ± 0.042      1.57 ± 0.02 0.45
Table  3.  Relation  between  obesity  and  tumor  grade  in 
breast cancer samples.
Tumor garde 
BMI (kg/m2)
1 2 + 3 P
nonobese (n = 31) 14 (63.6) 17 (41.5) 0.078
Obese (n = 32) 8 (38.4) 24 (58.5)Obesity and steroid receptors gene expression in breast cancer patients
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Table 5. Mean mRnA level of steroid hormone receptors gene expression in breast cancer tissues.
Mean ± se 
steroid hormones
none obese 
(BMI , 25 kg/m2) 
(n = 36)
Obese 
(BMI $ 25 kg/m2) 
(n = 34)
P
eRα 11.73 ± 0.41   7.40 ± 0.46 ,0001
eRβ   8.01 ± 0.53 14.15 ± 0.64 ,0001
PR   5.82 ± 0.27   3.79 ± 0.28 ,0001
AR   2.44 ± 0.334   2.08 ± 0.25 0.40
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Figure 1. (A and B) eRβ standard curve (R2 = 0.97, M = -3.3, e = 100).esfahlan et al
234  Breast Cancer: Basic and Clinical Research 2011:5
detection  assays  but  none  evaluated  the    possible 
impact  of  obesity  on  expression  of  other    steroid 
receptors gene expression such as   androgen and pro-
gesterone receptor and specially ERβ. So we used 
real-time quantitative RT-PCR to assess steroid hor-
mone  receptors  gene  expression  in  human  breast 
tumors. This recent approach to nucleic acid quan-
tification is suited to the development of target gene 
assays,  having  a  high  degree  of  inter-  laboratory 
standardization and also yielding statistical confi-
dence values.
Obesity and steroid hormone  
receptors gene expression  
in breast cancer patients
Our results show that the difference in ERα mRNA 
level between normal and obese patients was significant 
(P , 0.001) and the expression of ERα mRNA was 
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Figure 2. Amplification (A) and Melting curve (B) of eRβ mRnA in breast cancer samples, 83 °C.Obesity and steroid receptors gene expression in breast cancer patients
Breast Cancer: Basic and Clinical Research 2011:5  235
found to be highest in obese samples. This   finding is 
in relation to that of Dario Giuffkida 1992, Cleary MP 
1997, Maehle BO 1996, and Nomura Y 1984.13,14,23,24 
We confirm their finding that estrogen receptor (ER)-
positive tumors are more likely to be associated with 
obesity than are ER-negative tumors.
An article published by Dario Giuffrida D and et al 
in 1992 is the only study which is partially similar to 
ours. They studied the relation between steroid recep-
tor status and body weight in breast cancer patients 
via protein assay methods. They assessed the rela-
tionship between the ER and progesterone receptor 
(PR) status of the neoplastic tissue and obesity in a 
series of 615 breast cancer patients. Both ER and PR 
concentrations were significantly and positively cor-
related with obesity by multiple regression   analysis. 
Furthermore, the estimated probability of having an 
ER+/PR+ carcinoma was significantly higher in obese 
patients  (odds  ratio  2.65,  95%  confidence  interval 
1.56–4.48).13
According  to  Dario  and  our  findings,  it  can  be 
concluded that obese cases have a high expression of 
ERα  and  PR  mRNA  in  comparison  to  their  none 
obese counterparts.
For the first time we evaluated the possible impact of 
obesity on ERβ gene expression. We found that not 
only ERα mRNA level can be affected by excessive 
adipose tissue, but the mRNA level of ERβ which has a 
paramount importance in regulating the ERα mRNA 
level can be affected directly by obesity or indirectly by 
increased  ERα  expression  in  obese  breast  cancer 
patients. According to the results of our study, it seems 
that in patients with breast cancer, not only ERα but 
also ERβ and PR gene expression can be affected by 
obesity and for achieving a better result in obese sub-
jects both estrogen receptors can be candidate as poten-
tial target therapies. In case of AR, like Bieche we find 
a positive correlation between AR and ERα but in con-
trast to Bieche in our study no correlation was observed 
between AR and ERβ mRNA level.25 Likewise, AR is 
expressed in approximately 70% to 90% of invasive 
breast cancers, a frequency comparable with or higher 
than  the  one  reported  for  ER  (70%–80%)  and  PgR 
(50%–70%).26  In  our  study,  AR  mRNA  expression 
ranked the highest expression while ERβ was the low-
est.   Moreover there was no difference in AR mRNA 
between two obese and none obese cases. Although a 
relationship between AR and both ER and PR status has 
been demonstrated, a significant percentage of tumors 
are positive for AR and negative for ER and PR. This 
finding reveals the independent expression of AR in 
human breast cancer as we find no relation between AR 
and BMI in our study so it seems that AR is less affected 
by obesity rather than other steroid hormones.
Relation between steroid receptors  
gene expression with clinicopatological 
parameters
Studies have confirmed the relation between high 
grade and ER negativeness in breast cancer tissues. 
In one study by Bieche et al27 statistically signifi-
cant links were found between ERα gene status (but 
not ERβ gene status) and Scarff-Bloom-  Richardson 
(SBR) histopathological grade (P = 0.00029) and 
ERα and ERβ status were not significantly linked 
to lymph-node status or macroscopic tumor size. In 
another study de Cremoux found a significant cor-
relation between ERα and tumor grade (P = 0.03) 
but no correlation was observed with other clinical 
or pathological parameters and no correlation was 
found between ERβ mRNA level and tumor size, 
nodal   status, grade, histological size. In our study 
there was a significant relation between ER α and 
tumor stage (P = 0.45) and also between AR and 
Table 6. Observed frequency (%) of AR mRnA in different 
grades of breast cancer.
Tumor garde 
AR mRnA level
1 2 + 3 P
Low (n = 33) 10 (27.8) 26 (72.2)
0.046 high (n = 30) 14 (51.9) 13 (48.1)
Table 7. Observed frequency (%) of eRα mRnA in different stages of breast cancer.
Tumor stage 
eRα mRnA level
1 2A 2B 3A 3B 4 P
Low (n = 36) 0 (0.0) 12 (36.4) 8 (24.2) 9 (27.3) 4 (12.1) 0 (0)
0.045 high (n = 27) 2 (6.7) 13 (43.3) 5 (16.7) 1 (3.3) 8 (26.7) 1 (3.3)esfahlan et al
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tumor grade (P = 0.046) but there was no signifi-
cant relation between the ERβ and PR with tumor 
stage and tumor grade. Just like many other research-
ers such as   Cremoux Speirs V, Knoweldton JM and 
Cullen R it seems that ERα expression more than 
ERβ expression correlated with clinicopathological 
parameters in breast cancer tumors.8,28–30 similar to 
Bieche et al’s findings, it seems that AR can act as an   
independent  factor  and  can  affect  progression  of 
mammary cells. Several studies have reported an 
association between high body weight and axillary 
lymph node involvement.31–33 Williams et al inves-
tigated the relationship of body weight to response 
to endocrine therapy, steroid hormone receptors and 
survival  of  patients  with  advanced  cancer  of  the 
breast.  High  body  weight  was  correlated  with 
advanced tumor stage (P = 0.002), but not with the 
presence of estrogen receptor (total ER P = 0.21).17
Giuffrida et al presented findings from prognostic 
parameters of tumor evaluation as tumor size, pres-
ence of metastatic lymph nodes, tumor grade and his-
totype were available in 538 patients, no significant 
correlation by an overall F test from one-way analysis 
of variance was found between the patient BMI and 
any of these parameters. As with Giuffrida, in our 
study also there was no significant relation between 
BMI and tumor stage but obese individuals were in 
high stages and had a larger tumor size.
Maehle and Teitli investigated 1,238 women with 
unilateral breast cancer treated with modified radical 
mastectomy living in the geographic area of Hauke-
land Hospital. Age-  adjusted Quetelet’s index (weight/
height2) showed that obese women had a 49% higher 
risk of dying from breast cancer than lean ones. The 
relative  risk  decreased  slightly  when  adjusted  for 
tumor diameter, lymph node status, and mean nuclear 
area of the tumor cells. They found that in patients 
with  a  hormone  receptor  positive  tumor,  obese 
women had a risk that was more than three times 
higher  than  lean  ones.  In  patients  with  hormone 
receptor negative tumor, the effect of obesity was 
reversed, lean patients having a risk that was more 
than  six  times  higher  than  obese  ones,  even  after 
adjustment.23
It seems that in obese ER positive subjects, beside 
obesity, the role of other factors (eg, serum level of 
  adipocyte-derived hormones) should be considered too.
Final conclusion
In summary, according to the obtained results, it is 
speculated that obesity could play a significant role in 
steroid  receptors  gene  expression  and  also  could 
affect progression and proliferation of breast cancer 
cells.
Acknowledgments
This work financially supported by Iranian National 
Science Foundation (INSF) with the ref code (8800060-
April12/2010). We appreciate all individuals who par-
ticipated in this study.
Disclosures
Author(s) have provided signed confirmations to the 
publisher of their compliance with all applicable legal 
and  ethical  obligations  in  respect  to  declaration  of 
conflicts  of  interest,  funding,  authorship  and 
  contributorship, and compliance with ethical require-
ments in respect to treatment of human and animal test 
subjects.  If  this  article  contains  identifiable  human 
subject(s)  author(s)  were  required  to  supply  signed 
patient consent prior to publication. Author(s) have 
confirmed that the published article is unique and not 
under consideration nor published by any other publi-
cation and that they have consent to reproduce any 
copyrighted material. The peer reviewers declared no 
conflicts of interest.
References
1.  Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adi-
ponectin: molecular mechanisms and potential therapeutic intervention. Clin 
Sci (Lond). 2008;114(5):361–74.
2.  Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic 
review. Br J Cancer. 2006;94(9):1221–5.
3.  Hou WK, Xu YX, Yu T, Zhang L, Zhang WW, Fu CL et al. Adipocytokines 
and breast cancer risk. Chin Med J (Engl). 2007;120(18):1592–6.
4.  Sellers TA, Kushi LH, Potter JD, et al. Effect of family history, body-fat 
distribution, and reproductive factors on the risk of postmenopausal breast 
cancer. N Engl J Med. 1992;326(20):1323–9.
5.  Edman CD, Aiman EJ, Porter JC and MacDonald PC: Identification of the 
estrogen product of extraglandular aromatization of plasma androstenedione. 
Am J Obstet Gynecol. 1978;130:439–47.
6.  Speirs  V,  Walker  RA.  New  perspectives  into  the  biological  and  clinical 
relevance of oestrogen receptors in the human breast. J Pathol. 2007;211(5): 
499–506.
7.  Loi S, Milne RL, Friedlander ML, et al. Obesity and outcomes in premeno-
pausal  and  postmenopausal  breast  cancer.  Cancer  Epidemiol  Biomarkers 
Prev. 2005;14(7):1686–91.
8.  Cullen R, Maguire TM, McDermott EW, Hill AD, O’Higgins NJ, Duffy MJ. 
Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer. Eur J 
Cancer. 2001;37(9):1118–22.
9.  Matthews J, Gustafsson JA. Estrogen signaling: a subtle balance between ER 
alpha and ER beta. Mol Interv. 2003;3(5):281–92.publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
Obesity and steroid receptors gene expression in breast cancer patients
Breast Cancer: Basic and Clinical Research 2011:5  237
  10.  Markey GC, Cullen R, Diggin P, Hill AD, Mc Dermott EW, O’Higgins NJ 
et al. Estrogen receptor-beta mRNA is associated with adverse outcome in 
patients with breast cancer. Tumour Biol. 2009;30(4):171–5.
 11.  Skliris GP, Carder PJ, Lansdown MR, Speirs V. Immunohistochemical detec-
tion of ERbeta in breast cancer: towards more detailed receptor profiling? 
Br J Cancer. 2001;84(8):1095–8.
  12.  Zhao C, hlman-Wright K, Gustafsson JA. Estrogen receptor beta: an over-
view and update. Nucl Recept Signal. 2008;6:e003.
  13.  Giuffrida D, Lupo L, La Porta GA, et al. Relation between steroid receptor 
status and body weight in breast cancer patients. Eur J Cancer. 1992;28(1): 
112–5.
  14.  Cleary MP, Maihle NJ. The role of body mass index in the relative risk of 
developing premenopausal versus postmenopausal breast cancer. Proc Soc 
Exp Biol Med. 1997;216(1):28–43.
  15.  Folsom AR, Kaye SA, Prineas RJ, et al. Increased incidence of carcinoma 
of the breast associated with abdominal adiposity in postmenopausal women. 
Am J Epidemiol. 1990;131(5):794–803.
  16.  Verla-Tebit E, Chang-Claude J. Anthropometric factors and the risk of pre-
menopausal breast cancer in Germany. Eur J Cancer Prev. 2005;14:419–26.
  17.  Williams G, Howell A, Jones M. The relationship of  body weight to response 
to endocrine therapy, steroid hormone receptors and survival of patients 
with advanced cancer of the breast. Br J Cancer. 1988;58(5):631–4.
  18.  Carmichael AR, Bendall S, Lockerbie L, Prescott RJ, Bates T. Does obesity 
compromise survival in women with breast cancer? Breast. 2004;13(2):93–6.
  19.  Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. 
Breast. 2004;13(2):85–92.
  20.  Tough IC, Carter DC, Fraser J, Bruce J. Histological grading in breast 
cancer. Br J Cancer. 1969;23(2):294–301.
  21.  WHO.  Histological  typing  of  breast  tumors.  Geneva.  1981.  Ref  Type: 
Internet Communication.
22.  Thoresen S. Histological grading and clinical stage at presentation in breast 
carcinoma. Br J Cancer. 1982;46(3):457–8.
  23.  Maehle BO, Tretli S, Skjaerven R, Thorsen T. Premorbid body weight and 
its relations to primary tumour diameter in breast cancer patients; its depen-
dence on estrogen and progesteron receptor status. Breast Cancer Res Treat. 
2001;68(2):159–69.
  24.  Nomura Y, Tashiro  H,  Hamada Y,  Shigematsu T.  Relationship  between 
estrogen receptors and risk factors of breast cancer in Japanese pre- and 
postmenopausal patients. Breast Cancer Res Treat. 1984;4(1):37–43.
  25.  Bieche I, Parfait B, Tozlu S, Lidereau R, Vidaud M. Quantitation of androgen 
receptor gene expression in sporadic breast tumors by real-time RT-PCR: 
evidence that MYC is an AR-regulated gene. Carcinogenesis. 2001;22(9): 
1521–6.
  26.  Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC 
et al. Androgen receptor expresion in breast cancer: relationship with clini-
copathological characteristics of the tumors, prognosis, and expression of 
metalloproteases and their inhibitors. BMC Cancer. 2008;8:149.
  27.  Bieche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R. Quanti-
fication of estrogen receptor alpha and beta expression in sporadic breast 
cancer. Oncogene. 2001;20(56):8109–15.
  28.  de CP, Tran-Perennou C, Elie C, Boudou E, Barbaroux C, Poupon MF et al. 
Quantitation of estradiol receptors alpha and beta and progesterone recep-
tors in human breast tumors by real-time reverse transcription-polymerase 
chain reaction. Correlation with protein assays. Biochem Pharmacol. 2002; 
64(3):507–15.
  29.  Valerie S, Alicia T, Michael J, et al. Coexpression of Estrogen Receptor a 
and  β  Poor  Prognostic  Factors  in  Human  Breast  Cancer?  Cancer  Res. 
1999;595:25–528.
  30.  Knowlden JM, Gee JM, Robertson JF, Ellis IO, Nicholson RI. A possible 
divergent role for the oestrogen receptor alpha and beta subtypes in clinical 
breast cancer. Int J Cancer. 2000;89(2):209–12.
  31.  Greenberg ER, Vessey MP, McPherson K, Doll R, Yeates D. Body size and 
survival in premenopausal breast cancer. Br J Cancer. 1985;51(5):691–7.
  32.  Abe  R,  Kumagai  N,  Kimura  M,  Hirosaki  A,  Nakamura  T.  Biological 
characteristics of breast cancer in obesity. Tohoku J Exp Med. 1976;120(4): 
351–9.
  33.  Eberlein T, Simon R, Fisher S, Lippman ME. Height, weight, and risk of 
breast cancer relapse. Breast Cancer Res Treat. 1985;5(1):81–6.
  34.  Pfeiler GH, Buechler C, Neumeier M, et al. Adiponectin effects on human 
breast cancer cells are dependent on 17-beta estradiol. Oncol Rep. 2008; 
19(3):787–93.
  35.  Pfaffl MW, Lange IG, Daxenberger A, Meyer HH. Tissue-specific expres-
sion pattern of estrogen receptors (ER): quantification of ER alpha and ER 
beta mRNA with real-time RT-PCR. APMIS. 2001;109(5):345–55.